

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴:

A61K 9/00

A1

(11) International Publication Number:

WO 89/ 07935

(43) International Publication Date: 8 September 1989 (08.09.89)

(21) International Application Number: PCT/US89/00348

(22) International Filing Date: 27 January 1989 (27.01.89)

(31) Priority Application Number: 162,161

(32) Priority Date: 29 February 1988 (29.02.88)

(33) Priority Country: US

(71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).

(72) Inventors: MATHIOWITZ, Edith : 42 Alton Place, Brookline, MA 02146 (US). LANGER, Robert S. : 46 Greenville Street, Somerville, MA 02143 (US). WARSHAWSKY, Abraham : 26 Hanasi Harishon, 76 302 Rehovot (IL). EDELMAN, Elazar : 45 Longwood Avenue, Apt. #308, Brookline, MA 02146 (US).


(74) Agent: PABST, Patrea, L.: Kilpatrick & Cody, 100 Peachtree Street, Suite 3100, Atlanta, GA 30043 (US).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report.

(54) Title: POLYMER COMPOSITE FOR CONTROLLED RELEASE OR MEMBRANE FORMATION



(57) Abstract

The present invention is a method to produce composites based on microcapsules or microspheres embedded in continuous polymeric matrices. Both non-bioerodible and erodible polymers can be used. Material can be incorporated into the microcapsules or microspheres for subsequent release. The polymer composites have completely different properties from either a continuous polymer matrix or microcapsules or microspheres and are therefore useful for a wide variety of applications. Figure 1 is a graph of the percent cumulative release of acid orange from microspheres of a polycarboxyphenoxypropane-sebacic acid copolymer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-/-

POLYMER COMPOSITE FOR CONTROLLED RELEASE
OR MEMBRANE FORMATION

Background of the Invention

The Government has rights in this invention pursuant to Grant Number 5-R01-GM26698 awarded by the Department of Health and Human Services.

5 The present invention is generally in the area of polymeric matrices containing microspheres or microcapsules for controlled release of encapsulated compounds or modification of the polymer matrix.

10 The use of microcapsules for controlled drug delivery or implantation of cells or other materials into a patient is well known. For example, U.S. Patent Number 4,352,883 to Lim describes the microencapsulation of a variety of substances. U.S. Patent No. 3,464,413 to Goldfarb et al. discloses
15 bandages containing microcapsules which release drugs when ruptured. Similarly, the use of biocompatible, bioerodible polymeric implants, such as the devices made from polyglycolic acid, polylactic acid or polyanhydrides, are also well known. K.W. Leong et al
20 describe the use of polyanhydride implants for controlled drug delivery in "Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics", J.Biomedical Mater., 19,941-955
25 (1985).

Outside of the controlled drug delivery area, there has been little utilization or development of microcapsule or polymeric devices for controlled release of materials embedded within the polymers.
30 Even within the area of controlled drug delivery, it has been difficult, if not impossible, to achieve the

-2-

desired release kinetics for a bioactive substance from either polymer films or microcapsules. The preferred type of release occurs relatively linearly over time ("zero order kinetics"), not irregularly as
5 a function of variations within the polymer chains or the relative thicknesses of different portions of the device. Even with spheres of apparently uniform diameter, linear release is not obtained.

It is therefore an object of the present
10 invention to provide a method and means for forming a polymer matrix containing a uniform distribution of microcapsules or microspheres including bioactive or other compounds.

It is another object of the present invention to
15 provide a method and means for releasing bioactive or other compounds from a polymeric matrix at a desired rate and quantity.

It is a further object of the present invention to provide a method and means for controlled release
20 of bioactive or other compounds from a polymer matrix which can be controlled by external stimuli such as light, temperature, or ultrasound.

It is yet another object of the present invention to provide a method and means for forming a
25 permeable or porous polymeric membrane after the polymer is polymerized and formed into the desired shape.

SUMMARY OF THE INVENTION

The present invention is a method and means for
30 constructing polymer composites containing microcapsules or microspheres. The polymeric matrices and the microspheres or microcapsules may be formed of either

-3-

biodegradable or non-degradable polymers including polyanhydrides, polyorthoesters, polystyrene, polyurethane, polypropylene, polymethacrylate, polyglycolic acid, polylactic acid, and other known
5 polymers. As used herein, microcapsules are spheres having a central cavity and microspheres are solid spheres (as used herein, "spheres" refers generally to either microcapsules or microspheres).

In one embodiment, the spheres contain compound
10 to be released. In another embodiment, the spheres are removed from the matrix after polymerization of the surrounding matrix to form a permeable or porous polymeric membrane. The diameter of the spheres in the polymer matrix may be optimized to control the
15 rate of release and the quantity of release or the resulting pore size.

A variety of polymer combinations can be designed to encapsulate bioactive materials including drugs, insecticides, and herbicides and inorganic or
20 organic compounds such as dyes, flame retardants, or solvents.

In one variation of the first embodiment, spheres containing an encapsulated compound are homogeneously dispersed within a polymer matrix for
25 release of the compound following exposure of the matrix to heat, UV light, or ultrasound. In another variation of this embodiment, erodible polymers or a combination of erodible and non-degradable polymers are used to construct spheres such that release occurs
30 as a function of the degradation of the erodible polymer. In variations of the second embodiment, release of an encapsulated compound, such as a foaming agent, or degradation of spheres formed of degradable

-4-

polymers is used to modify the polymeric matrix, for example, to create a porous structure.

The polymer composites have a variety of uses. For example, when carbon tetrachloride is encapsulated within spheres embedded within a polymeric matrix having a relatively low melting point, the system forms an effective flame retardant barrier. Porous polymer matrices formed through release of a gas-forming material within the microcapsules embedded within the matrix have applicability as transdermal drug delivery devices, vascular grafts, and wound coverings. The latter is particularly useful since the pores can be created after polymerizing and situating the composite. Due to the extremely desirable release kinetics of encapsulated compounds from immobilized microcapsules, the composites are especially useful for controlled drug delivery.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph of the percent cumulative release of acid orange from microspheres of polycarboxyphenoxy propane copolymerized with sebacic acid p(CCP:SA)(20:80), having diameters of 50 to 212, 212 to 300, 300 to 425, 600 to 710, and 850 to 1100 microns, with 5% loading of acid orange, over time (hours).

Figure 2 is a graph of the release of acid orange from microspheres of pCCP:SA (20:80), diameter 300 to 425 microns, embedded in a polyurethane matrix over time (hours).

Figure 3 is a photograph of polyamide microcapsules embedded in polystyrene (x 60).

-5-

Figure 4 are graphs of the cumulative release of heparin (micrograms) from polylactic acid microspheres with 20% heparin loading embedded in polyurethane (0.2 g microspheres in 1 g polymer) over time (hours).
5 Four identical samples were compared (Figures a, b, c, and d).

Figure 5 is a graph of the cumulative release of heparin from polylactic acid microspheres with 20% heparin loading embedded in polystyrene (0.2 g 100-
10 300 microspheres in 1 g polymer) over time (hours).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is a method and means for constructing polymer composites containing microcapsules or microspheres for subsequent release
15 of encapsulated compounds or modification of the polymer matrix.

In one embodiment a compound is encapsulated within microcapsules or incorporated into microspheres which are then uniformly embedded in a polymer matrix.
20 Upon exposure to a specific stimuli or degradation of the microcapsule or microsphere, the compound is released. In a second embodiment the compound is released to modify the surrounding polymeric matrix.

Microcapsules and microspheres (jointly referred
25 to herein as "spheres") can be constructed using methods known to those skilled in the art. For example, spheres can be formed by interfacial polymerization, hot melt microencapsulation, solvent removal, solvent evaporation, or methods such as those
30 described in U.S. Serial No. 045,840 filed May 1, 1987 by Edith Mathiowitz and Robert S. Langer entitled "Multiwall Polymeric Microcapsules" and U.S. Serial

-6-

No. 025,409 filed March 13, 1987 by Edith Mathiowitz et al. entitled "Preparation of Polyanhydride Microspheres and Use in Controlled Drug Delivery". Exemplary methods applied to specific polymers are summarized as follows.

Polyamide microcapsules can be constructed by interfacial polymerization using the method of Edith Mathiowitz et al. in "Photochemical Rupture of Microcapsules: A Model System", J. App. Polym. Sci., 26 809 (1981). Briefly, an aqueous solution of the amine and polyvinyl alcohol are added to a suspension of a benzene:xylene solution (2:1, v/v) of the dichloride in water. Azobisisobutironitrile (AIBN) and/or azobenzene are added to the organic solution. The polycondensation reaction is allowed to continue for a desired period of time. Microcapsules are separated by decantation, repeatedly washed with distilled water and dried by rapid washing with acetone. As described, the amine:chloride ratio, in equivalent units, are held constant.

Polyanhydride microspheres can be formed by hot melt microencapsulation by mixing melted polymer with solid particles of the substance to be encapsulated, such as a dye or drug. This method, applicable only when the substance to be encapsulated is stable at the melting point of the polymer, is described by E. Mathiowitz and R. Langer in "Polyanhydride Microspheres as Drug Carriers I. Hot Melt Encapsulation", J. Controlled Release, 5, 13-22 (1987). The mixture is suspended in a non-miscible solvent, heated 5°C above the melting point of the polymer, and stirred continuously. Once the emulsion is stabilized, it is cooled until the core material solidifies. The solvents used to make the

-7-

microcapsules in the following examples were silicon and olive oil. The particle size of the compound to be encapsulated was selected to always be less than 50 microns. The spheres are washed by decantation with
5 petroleum ether to produce a free flowing powder.

One method of preparing polyanhydride spheres by solvent removal is described by Edith Mathiowitz et al. in "Polyanhydride Microspheres as Drug Carriers." II. Microencapsulation by Solvent Removal", J. Appl. Poly. Sci. (1987). As applied to the production of polycarboxyphenoxypropane:sebacic acid (20:80) 16,000 molecular weight spheres, 1 g polymer is dissolved in 1 ml methylene chloride. The compound to be
15 encapsulated is mixed into the solution, dropped into silicon oil (Dow Chemical Co, Midland, MI) containing between 1 to 5% of SpanTM 85 and stirred. After 1 hour, petroleum ether is added to the mixture and stirring continued for another hour. The spheres are isolated by filtration, washed with petroleum ether,
20 and dried overnight in a lyophilizer.

When higher molecular weights polymers with higher percentages of carboxyphenoxypropane (CPP) are used, a different method is required. 2 g polymer is dissolved in 10 ml methylene chloride, the compound to
25 be encapsulated is added, and the mixture suspended in silicon oil containing SpanTM 85 and a known amount of methylene chloride. The amount of methylene chloride depends on the type and molecular weight of the polymer used. For example, for pCPP:SA (20:80) having
30 a molecular weight of 30,000 to 40,000, the ratio between the silicon oil and the methylene chloride is 4:1. For pCPP:SA (50:50) having a molecular weight 40,000, the ratio between the silicon oil and the methylene chloride is 1:1. After dropping the polymer

-8-

solution into the silicon oil, petroleum ether is added and stirred for two hours. Spheres are isolated by filtration, washed with petroleum ether, dried overnight in a lyophilizer, and stored in a freezer.

- 5 Methods for preparation of spheres by solvent evaporation, a method well known to those skilled in the art, are described by S. Yolles et al., "Controlled Release of Biologically Active Agents" in Controlled Release Polymeric Formulation, D.R. Paul
10 and F.W. Harris, Editors, American Chemical Society Symposium, Washington, D.C. 33, 123-134 (1976); L.R. Beck et al., Fertil. Steril., 31, 545-551 (1979); H. Jaffe, U.S. Patent 4,272,398, June 9, (1981); J.A. Setterstrom et al., Proceeding of the 1982 Army
15 Science Conference, Vol 3, 215-226 (West Point, New York 1982); S. Benita et al, J. Pharm. Sci., 73, 1721-1724 (1984); and A.K. Kwong et al., J. Controlled Release, 4, 47-62 (1986).

- 20 In one embodiment, the spheres are encapsulated within the polymer by dissolving the embedding polymer in an organic solvent to produce a viscous solution and then suspending the spheres in the polymer solution. The polymer is preferably dissolved in just enough organic solvent to produce a viscous
25 solution. This allows for a more homogeneous suspension of spheres. Highly volatile solvents are selected to dissolve the embedding polymer so as to enhance rapid solidification of the solution and thereby prevent the spheres from settling. The
30 organic solvent must not dissolve the polymeric spheres.

 Examples of polymer-solvent systems include: polystyrene in CH_2Cl_2 , ethylenevinyl acetate in

-9-

CH₂Cl₂, polyurethane in tetrahydrofuran, polyvinylamide in water, and polystyrene in toluene.

Another way to embed the spheres in the polymer matrix is to disperse the spheres into melted polymer.

- 5 Still another method is to mix the spheres with particles of polymer, then compress the mixture into the desired shape. Caution must be exercised however to prevent rupture of microcapsules using this method.

- The types of polymer used to form the spheres and the matrix are determined by the application, taking into consideration possible interactions between the polymers used to form the spheres and the polymer used for the matrix. Polymers which are not miscible in each other are preferred so that the integrity of the spheres is maintained during the formation of the composite. In some biomedical applications, it is desirable to use polymer for the spheres which erode before the polymers forming the matrix. For other applications, a non-erodible matrix polymer in combination with spheres formed of erodible polymers is favored. For instance, small erodible spheres of polylactic acid or polyanhydrides in a non-erodible matrix of polyurethane or polystyrene can be employed to form a porous structure.

- 25 A unique application is the production of membranes with changing or variable porosity, which is achieved by rupture or erosion of encapsulated spheres. Photochemical rupture of microcapsules is described by E. Mathiowitz et al. in J. Appl. Poly. Sci., 26, 809-822 (1981). Temperature release is obtained by heating the microcapsules described in (Mathiowitz, et al. in J. Appl. Poly. Sci.). Release using ultrasound is described by Kost et al in

-10-

"Ultrasonic Modulated Drug Delivery Systems" in Polymers in Medicine: Biomedical and Pharmaceutical Applications II., E. Chellini, editor (1987).

The type of release is an important factor in
5 determining which polymers to use, as well as the
method utilized to make the composite and whether
microcapsules or microspheres are preferred. For
example, sudden versus sustained release have
different requirements. When sudden release is
10 desired, the reservoir-type device encapsulated inside
a film is selected (polyamide microcapsules inside a
polyurethane matrix). For controlled release of
bioactive substances in vivo, one would choose
biodegradable or rupturable microcapsules or
15 microspheres in a biodegradable implant shaped
appropriately for the site and rate of release
(polyanhydride microspheres or microcapsules inside a
polyanhydride matrix). For creation of a vascular
graft, rapidly erodible or rupturable microspheres can
20 be entrapped within an extruded tube-shaped slower
degrading polymer matrix. Rapid erosion of the spheres
results in pores for immediate cell seeding and
vascularization, with the matrix providing support
until cell growth becomes confluent and acquires
25 structural integrity.

A major advantage of the present invention is
the versatility of application. Structures ranging
from flame retardant films to erodible vascular grafts
and drug delivery systems to porous polymeric
30 membranes can be constructed. The size and shape of
the matrix, and means used to configure it, can be
tailored as needed. Similarly, the type of polymer,
the diameter and fabrication of the spheres, and the

-11-

content of the spheres can be fashioned as dictated by the function.

As used herein, "compounds" includes both liquid and solid drugs, insecticides, herbicides, other
5 bioactive compounds, inorganic and organic solvents, dyes, foaming agents, flame retardants, antioxidants, biocidal compounds, lubricants, surfactants, etc. Substances to be released can be dissolved in the embedding polymer, dissolved into the polymer forming
10 the microcapsule or microsphere, or encapsulated within the microcapsules. Considerations in selecting both the polymer-solvent system and the compound to be released include the stability of the compound to be encapsulated, the desired loading of the compound to
15 be released (g compound/g polymer or ml compound/g polymer), the release kinetics, the solubility of the compound in the polymers, and the means by which the compound is to be released.

For example, flame retardant polymer film can be
20 produced by encapsulating carbon tetrachloride within polyamide microcapsules which are then embedded in a polyurethane or polystyrene polymer matrix. The matrix and microcapsule polymers rupture upon exposure to a preselected temperature, thereby
25 releasing the carbon tetrachloride. Other flame retardant materials could be used, as could foaming agents, surfactants, or lubricants whose release in the presence of high heat is desired. The microcapsule-polymer matrices could also be used as a
30 delivery system for an antioxidant or a preservative within a sealed container where release of the encapsulated compound is achieved by exposure to ultrasound or light. Alternatively, the polymer composites can be used to release fertilizer,

-12-

insecticides, or herbicides using ultrasound, light or temperature as the release mechanism.

The present invention is further described by the following non-limiting examples.

5 Example 1. Release of a dye from microcapsules not embedded in a matrix.

For purposes of comparison, polycarboxyphenoxypropane:sebacic acid
10 p(CPP:SA) (20:80) microspheres having diameters between 50 to 212, 212 to 300, 300 to 425, 600 to 710, and 850 to 1100 microns were prepared with 5% acid orange loading. As shown in Figure 1, when immersed in 40 ml of NaH_2PO_4 buffer solution at pH 7.4, between 50 to
15 80% of the acid orange is released within 5 hours. Release is non-linear in most cases. Release is complete within several hours.

Example 2. Release of acid orange from p(CPP:SA) (20:80) microspheres
20 embedded in polyurethane.

Approximately zero order release kinetics are demonstrated by Figure 2 shows release of acid orange from p(CPP:SA) (20:80) microspheres with 5% loading of acid orange which are embedded in a matrix of
25 polyurethane. The microspheres have a diameter of 300-425 microns. The polymer matrix has a diameter of 1 mm. Release occurs over an extended period of time, approximately one month. This is in sharp contrast to the release displayed in Figure 1. Not only is the
30 compound released over a greater period of time, but a substantially more linear release is obtained at the initial stages.

-13-

Example 3. Release from Polyamide microcapsules embedded in polystyrene by exposure to high temperature.

5 A micrograph showing uniform distribution of polyamide microcapsules throughout the polystyrene matrix is shown in Figure 3. The matrix was left for 3 days at 100°C, causing the rupture of some of the microcapsules and release of their contents.

10 Example 4. Release of heparin from polylactic acid microspheres embedded in a polyurethane or polystyrene matrix.

Heparin was loaded into polylactic acid
15 microcapsules at 20% loading, i.e., 0.2 g heparin into 0.8 g polymer, which were then embedded in a polyurethane matrix. The release of the heparin from the microcapsules embedded in polyurethane is shown in Figure 4. Four identical samples are compared in
20 Figures 4a, 4b, 4c and 4d. It can be seen that the heparin is released when the matrix is immersed in 40 ml of NaH_2PO_4 , pH 7.4, with approximately zero order kinetics due to embedding the microspheres in the polyurethane. Further, release is extended over a
25 period of some 600 hours. The results are highly reproducible.

Heparin containing microspheres embedded in polystyrene also show approximately zero order release over a period of some 600 hours when immersed in 40 ml
30 of NaH_2PO_4 , pH 7.4, as shown in Figure 5. The quantity of release from polystyrene embedded microcapsules is much lower than the release from polyurethane embedded microcapsules. This provides an

-14-

example of how one can modify release from microcapsules containing the same quantity of compound in order to achieve a different release rate and quantity.

5 Modifications and variations of the present invention, a method and means employing microcapsules or microspheres embedded in a polymer matrix will be obvious to those skilled in the art from the foregoing detailed description. Such variations and
10 modifications are intended to come within the scope of the appended claims.

We claim.

-15-

1. A composite polymeric device comprising:
polymer spheres, and
a polymer matrix,
wherein the spheres are distributed within
the matrix and contain a compound to be released
from the matrix.
2. The polymeric device of claim 1 wherein the
compound to be released is selected from the group
consisting of solvents, surface active agents,
lubricants, flame retardants, preservatives,
antioxidants, bioactive compounds, insecticides,
herbicides, fertilizers, and foaming agents.
3. The polymeric device of claim 2 wherein the
bioactive compound is a drug.
4. The polymeric device of claim 1 wherein the
polymers are selected from the group consisting of
polystyrene, polyethylene acetate, polyethylenevinyl
acetate, polyurethane, polyamide, polyacrylamide,
polymethacrylate, polylactic acid, polyglycolic acid,
polyanhydrides, polyorthoester, and derivatives
thereof.
5. The polymeric device of claim 1 comprising
at least one degradable polymer.
6. The polymeric device of claim 5 comprising a
bioactive compound in biodegradable microcapsules and
a biocompatible, biodegradable matrix for use as a
drug delivery device.

-16-

7. The polymeric device of claim 1 wherein the polymer spheres containing the compound to be released are ruptured by exposure to an external stimuli.

8. The polymeric device of claim 7 wherein the polymer matrix is ruptured by exposure to an external stimuli.

9. The polymeric device of claim 7 wherein the external stimuli is ultrasound, light, radiation or temperature.

10. A composite polymeric device comprising:
polymer spheres and
a polymer matrix,
wherein the spheres burst upon exposure to an external stimuli or degrade over time to yield a porous polymeric structure.

11. The polymeric device of claim 7 wherein the polymers are selected from the group consisting of polystyrene, polyethylene acetate, polyethylenevinyl acetate, polyurethane, polyamide, polyacrylamide, polymethacrylate, polylactic acid, polyglycolic acid, polyanhydrides, polyorthoester, and derivatives thereof.

12. The polymeric device of claim 10 for use as a porous polymeric membrane.

13. The polymeric device of claim 10 wherein the spheres have degraded to produce a porous structure.

-17-

14. The polymeric device of claim 10 for use as porous polymeric support for cell growth.

15. The device of claim 10 further comprising a gas which is released into the polymeric matrix to form a porous structure when the spheres burst.

16. A method for making a composite polymeric device comprising:

providing a compound to be released,

incorporating the compound to be released into polymer spheres, and

embedding the polymer spheres into a continuous polymer matrix.

17. The method of claim 16 wherein the polymer spheres are embedded within the continuous polymer matrix by

dissolving the embedding polymer in an organic solvent in which the polymer spheres are not soluble to produce a viscous solution,

suspending the polymer spheres in the polymer solution, and

removing the solvent.

18. The method of claim 17 wherein the polymer is dissolved in an amount of organic solvent which produces a viscous solution.

19. The method of claim 17 wherein the solvent is highly volatile and is rapidly removed by evaporation before the microspheres settle.

-18-

20. The method of claim 16 wherein the compound to be released is selected from the group consisting of solvents, lubricants, flame retardants, preservatives, antioxidants, bioactive compounds, insecticides, herbicides, fertilizers, and foaming agents.

21. The method of claim 16 wherein the polymers are selected from the group consisting of polystyrene, polyethylene acetate, polyethylenevinyl acetate, polyurethane, polyamide, polyacrylamide, polymethacrylate, polylactic acid, polyglycolic acid, polyanhydrides, polyorthoester, and derivatives thereof.

22. The method of claim 16 wherein the compound to be released is a drug, at least one polymers is biodegradable, and the drug is released by erosion of the erodible polymer.

23. A method for forming a porous membrane comprising providing polymer spheres, embedding the polymer spheres within a continuous polymeric matrix, and removing the polymer spheres.

24. The method of claim 23 further comprising encapsulating a gas forming compound within the polymer spheres and releasing the gas into the continuous polymeric matrix to produce a porous polymeric structure.

25. The method of claim 24 further comprising using the porous structure at a site for cell growth.

-19-

26. The method of claim 25 further comprising using the porous structure as a membrane of varying porosity.

27. The polymeric device of claim 3 wherein said polymer matrix can be applied directly to the skin of a patient.

28. The polymeric device of claim 9 wherein said polymer spheres are ruptured within said polymeric matrix by exposure to ultrasound, light, radiation, or temperature,

said polymer spheres contain a bioactive compound, and

the bioactive compound diffuses out of said polymeric matrix following rupture of said polymer spheres.

1/5




FIGURE 1




FIGURE 2




FIGURE 5

3/5




FIG.3

4/5




FIGURE 4a




FIGURE 4b

5/5

FIGURE 4c





FIGURE 4d



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/00348

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(4): A61K 9/00		
US. CL: 424/486		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	424/425, 426, 486, 487	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US, A, 3,464,413 (GOLDIARB) 02 SEPTEMBER 1969. SEE COL. 6, LINES 42-71.	1-28
A	US, A, 3,839,220 (BARCHAS) 01 OCTOBER 1974 SEE COL. 3, LINE 58-COL. 4, LINE 5.	1-28
X	US, A, 3,909,444 (ANDERSON) 30 SEPTEMBER 1975. SEE THE ENTIRE DOCUMENT.	1-28
X	US, A, 3,921,636 (ZAFFARONI) 25 NOVEMBER 1975. SEE COL. 4, LINES 34-57.	1-28
A	US, A, 4,351,337 (SIDMAN) 28 SEPTEMBER 1982 SEE THE ENTIRE DOCUMENT.	1-28
X	US, A, 4,452,775 (KENT) 05 JUNE 1984 SEE THE ENTIRE DOCUMENT.	1-28
A	US, A, 4,618,629 (BUCHANAN) 21 OCTOBER 1986 SEE COL. 3, LINES 3-60.	1-28
A	US, A, 4,642,233 (URQUHART) 10 FEBRUARY 1987 SEE THE ENTIRE DOCUMENT.	1-28
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
14 APRIL 1989	17 MAY 1989	
International Searching Authority	Signature of Authorized Officer	
ISA/US	T. K. PAGE	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	US, A, 4,684,524 (ECKENHOFF) 04 AUGUST 1987 SEE THE ENTIRE DOCUMENT.	1-28
X	US, A, 4,708,861 (POPESCU) 24 NOVEMBER 1987 SEE EHT ENTIRE DOCUMENT.	1-28
X	US, A, 4,713,249 (SCHRODER) 15 DECEMBER 1987 SEE THE ENTIRE DOCUMENT.	1-28
X, P	US, A, 4,755,180 (AYER) 05 JULY 1988 SEE THE ENTIRE DOCUMENT.	1-28